{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:14:45Z","timestamp":1740179685552,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Rituximab (RTX), anti-CD 20 monoclonal antibodies, has been approved for many rheumatic and autoimmune diseases, the use of RTX is still limited due to financial constrain. Biosimilar RTX may increase access by offering patients a more affordable option, lead to improved patient outcomes. However, real-world data related to its immediate and short-term safety is scarce. This study aimed to evaluate the real-world immediate and short-term safety profiles of CT-P10, a biosimilar of Rituximab, in patients with rheumatic and autoimmune diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This prospective study included patients diagnosed with rheumatic or autoimmune diseases, aged\u2009\u2265\u200918\u00a0years, who were treated with biosimilar RTX at Siriraj or Ramathibodi Hospital during February 2019 to May 2019. Patients were followed up through 6\u00a0months after the infusions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 74 patients, with 124 infusions, 84% were females with mean age (SD) of 49.4 (15.7) years. The most common rheumatic and autoimmune disease included in this study was systemic lupus erythematosus (26%). All immediate adverse events (AEs) (15 out of 124 infusions) were mild requiring only symptomatic and supportive treatment. Short-term AEs included infection (N\u2009=\u200935), hematologic abnormalities (N\u2009=\u200933), chylous ascites (N\u2009=\u20091), and others (N\u2009=\u200910). Two deaths were related to serious bacterial and viral infection. Hematologic AEs comprised anemia (N\u2009=\u20095), neutropenia (N\u2009=\u200910), lymphopenia (N\u2009=\u200915), and thrombocytopenia (N\u2009=\u20093).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this real-world study, biosimilar RTX (CT-P10) has favorable immediate and short-term safety profiles. However, further studies with large sample size and long-term follow-up in real-world practice are still required to confirm the result.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s41927-022-00306-7","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T06:43:45Z","timestamp":1669790625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real world safety of CT-P10 (anti-CD 20 monoclonal antibodies biosimilar) in rheumatic and autoimmune diseases"],"prefix":"10.1186","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8952-5967","authenticated-orcid":false,"given":"Wanruchada","family":"Katchamart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pintip","family":"Ngamjanyaporn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annop","family":"Orawongpaisarn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thossapoom","family":"Phubangkertphon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasimon","family":"Borrirukwisitsak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nichapa","family":"Dechapaphapitak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"issue":"4","key":"306_CR1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/cc11304","volume":"16","author":"PM Kasi","year":"2012","unstructured":"Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Clinical review: Serious adverse events associated with the use of rituximab\u2014a critical care perspective. Crit Care (Lond, Engl). 2012;16(4):231.","journal-title":"Crit Care (Lond, Engl)"},{"issue":"11","key":"306_CR2","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00296-010-1526-y","volume":"31","author":"YH Lee","year":"2011","unstructured":"Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int. 2011;31(11):1493\u20139.","journal-title":"Rheumatol Int"},{"issue":"5","key":"306_CR3","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390\u2013400.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"306_CR4","first-page":"CS133","volume":"17","author":"A Weissmann-Brenner","year":"2011","unstructured":"Weissmann-Brenner A, Brenner B, Belyaeva I, Lahav M, Rabizadeh E. Rituximab associated neutropenia: description of three cases and an insight into the underlying pathogenesis. Med Sci Monit Int Med J Exp Clin Res. 2011;17(11):CS133\u20137.","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"306_CR5","unstructured":"U.S. Department of Health and Human Service. Common Terminology Criteria for Adverse Events (CTCAE). 2017. [cited 2020 April 1]. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"306_CR6","unstructured":"The use of the WHO-UMC system for standardised case causality assessment. [cited 2020 April 12]. https:\/\/www.who-umc.org\/media\/164200\/who-umc-causality-assessment_new-logo.pdf."},{"issue":"8","key":"306_CR7","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/1756-185X.13596","volume":"22","author":"Y Shi","year":"2019","unstructured":"Shi Y, Wu Y, Ren Y, Jiang Y, Chen Y. Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis. 2019;22(8):1361\u201370.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"306_CR8","doi-asserted-by":"publisher","first-page":"e000034","DOI":"10.1136\/rmdopen-2014-000034","volume":"1","author":"JH Salmon","year":"2015","unstructured":"Salmon JH, Cacoub P, Combe B, Sibilia J, Pallot-Prades B, Fain O, et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. 2015;1(1):e000034.","journal-title":"RMD Open"},{"issue":"8","key":"306_CR9","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/art.30427","volume":"63","author":"D Tesfa","year":"2011","unstructured":"Tesfa D, Ajeganova S, H\u00e4gglund H, Sander B, Fadeel B, Hafstr\u00f6m I, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63(8):2209\u201314.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"306_CR10","first-page":"422","volume":"29","author":"SK Toprak","year":"2012","unstructured":"Toprak SK, Karaku\u015f S. Rituximab-related reversible hepatocellular damage. Turk J Haematol Off J Turk Soc Haematol. 2012;29(4):422\u20134.","journal-title":"Turk J Haematol Off J Turk Soc Haematol"},{"key":"306_CR11","first-page":"bcr-2017","volume":"2017","author":"A Daniel","year":"2017","unstructured":"Daniel A, Bagnato G, Vital E, Del Galdo F. Chylous ascites in a patient with an overlap syndrome: a surprising response to rituximab. BMJ Case Rep. 2017;2017:bcr-2017.","journal-title":"BMJ Case Rep."}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-022-00306-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-022-00306-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-022-00306-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T05:30:32Z","timestamp":1701495032000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-022-00306-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["306"],"URL":"https:\/\/doi.org\/10.1186\/s41927-022-00306-7","relation":{},"ISSN":["2520-1026"],"issn-type":[{"type":"electronic","value":"2520-1026"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"assertion":[{"value":"1 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Siriraj Institutional Review Boards (COA no. Si 671\/2018, Oct 18, 2018) and Ramathibodi Institutional Review Boards (COA no. MURA2019\/124, Jan 29, 2019)<b>.<\/b> Informed consent was obtained from all subjects involved in the study prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}